Black Diamond Therapeutics Inc

BDTXNASDAQ · USD
1.47USD0.00 (-3.29%)
222

Black Diamond Therapeutics Inc (BDTX) Historical Volatility

BDTX's 30 day historical volatility is 99.00%, in the 84th percentile of readings over the past year. This is a high percentile, meaning Black Diamond Therapeutics Inc shares have swung far more than usual. BDTX's 30 day implied volatility sits at 260.86%, with an IV Rank of 86.51%, leaving IV 161.86 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking BDTX historical volatility helps you see how much Black Diamond Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, BDTX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor BDTX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. BDTX's 30 day historical volatility, or BDTX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing BDTX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.

Historical Volatility

HV Percentile
84thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)99.00%

HV Percentile84th

Implied Volatility (30d)260.86%

IV Rank86.51%

IV Minus HV+161.86%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →